These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 9674037)

  • 1. [Long chronic course of hemiparkinson-plus with l-dopa maintained response].
    Arias M; Requena I; Lema C
    Rev Neurol; 1998 Jul; 27(155):94-5. PubMed ID: 9674037
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early-onset parkinsonism with dystonia. Clinical and biochemical differences from hereditary progressive dystonia or DOPA-responsive dystonia.
    Furukawa Y; Mizuno Y; Narabayashi H
    Adv Neurol; 1996; 69():327-37. PubMed ID: 8615147
    [No Abstract]   [Full Text] [Related]  

  • 3. Disturbed intracortical excitability in early Parkinson's disease is l-DOPA dose related: a prospective 12-month paired TMS study.
    Bares M; Kanovský P; Rektor I
    Parkinsonism Relat Disord; 2007 Dec; 13(8):489-94. PubMed ID: 17449315
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hemiparkinson-hemiatrophy syndrome: a transcranial magnetic stimulation study.
    Nardone R; Lochner P; Tezzon F
    Electromyogr Clin Neurophysiol; 2003 Jun; 43(4):235-40. PubMed ID: 12836589
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Arguments in favor of the early treatment of Parkinson's disease with L-Dopa].
    Broussolle E
    Rev Neurol (Paris); 1999 Jan; 155(1):27-33. PubMed ID: 10093845
    [No Abstract]   [Full Text] [Related]  

  • 6. Levodopa in the early treatment of Parkinson's disease.
    Murata M
    Parkinsonism Relat Disord; 2009 Jan; 15 Suppl 1():S17-20. PubMed ID: 19131036
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Dystonia preceding dopa-responsive parkinsonism--heterogeneous clinical features].
    Miwa H; Mizuno Y
    No To Shinkei; 1996 Feb; 48(2):149-54. PubMed ID: 8865694
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Factors associated with motor fluctuations and dyskinesia in Parkinson Disease: potential role of a new melevodopa plus carbidopa formulation (Sirio).
    Stocchi F; Marconi S
    Clin Neuropharmacol; 2010 Jul; 33(4):198-203. PubMed ID: 20414107
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Does thalamotomy alter the course of Parkinson's disease?
    Tasker RR; DeCarvalho GC; Li CS; Kestle JR
    Adv Neurol; 1996; 69():563-83. PubMed ID: 8615182
    [No Abstract]   [Full Text] [Related]  

  • 10. Bilateral subthalamic nucleus stimulation for severe Parkinson's disease.
    Limousin P; Pollak P; Benazzouz A; Hoffmann D; Broussolle E; Perret JE; Benabid AL
    Mov Disord; 1995 Sep; 10(5):672-4. PubMed ID: 8552123
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sydney Multicenter Study of Parkinson's disease: non-L-dopa-responsive problems dominate at 15 years.
    Hely MA; Morris JG; Reid WG; Trafficante R
    Mov Disord; 2005 Feb; 20(2):190-9. PubMed ID: 15551331
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment strategies in Parkinson's disease after a quarter century experiences with L-DOPA therapy.
    Fischer PA
    J Neural Transm Suppl; 1995; 46():381-9. PubMed ID: 8821073
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dopa-responsive, nonprogressive juvenile parkinsonism: report of a case.
    Rajput A; Kishore A; Snow B; Bolton CF; Rajput AH
    Mov Disord; 1997 May; 12(3):453-6. PubMed ID: 9159748
    [No Abstract]   [Full Text] [Related]  

  • 14. Belly dystonia induced by levodopa and biperiden in a case of suspected multiple-system atrophy.
    Shan DE; Kwan SY; Ho HH; Su MS
    Mov Disord; 1996 Jul; 11(4):455-7. PubMed ID: 8813234
    [No Abstract]   [Full Text] [Related]  

  • 15. Effects of L-DOPA on spatiotemporal contrast sensitivity in Parkinson's disease.
    Mestre DR; Blin O; van den Brand CL; Azulay JP; Serratrice G
    Adv Neurol; 1996; 69():503-11. PubMed ID: 8615172
    [No Abstract]   [Full Text] [Related]  

  • 16. Parkinson's disease: progression and mortality in the L-DOPA era.
    Di Rocco A; Molinari SP; Kollmeier B; Yahr MD
    Adv Neurol; 1996; 69():3-11. PubMed ID: 8615142
    [No Abstract]   [Full Text] [Related]  

  • 17. The effect of levodopa dose and body weight on dyskinesia in a prevalent population of people with Parkinson's disease.
    Walker RW; Howells AR; Gray WK
    Parkinsonism Relat Disord; 2011 Jan; 17(1):27-9. PubMed ID: 21051272
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The 'magic' of L-dopa: why is it the gold standard Parkinson's disease therapy?
    Mercuri NB; Bernardi G
    Trends Pharmacol Sci; 2005 Jul; 26(7):341-4. PubMed ID: 15936832
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Daily defined doses of parkinsonian drugs in Alcoi].
    Manzanares R; Matías-Guiu J; Provencio R; Falip R; López-Arlandis J; Martín R; Ruiz C
    Rev Neurol; 1996 Apr; 24(128):440-2. PubMed ID: 8721923
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Parkinson "plus"].
    Fabre N; Brefel-Courbon C; Rascol O
    Rev Prat; 1997 May; 47(10):1077-82. PubMed ID: 9208670
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.